直接口服抗凝药在肾脏病患者中的作用
综述总结直接口服抗凝药(DOAC)在肾脏病患者中的现有文献。多数关键试验排除中重度肾病患者,但观察性研究提示DOAC疗效不劣于传统抗凝且出血风险更低。DOAC经肾清除且受蛋白尿及P-糖蛋白药物影响,特定肾病场景缺乏随机对照试验数据。
要点
- DOAC在肾病患者的观察性研究中显示疗效与出血优势
- 中重度肾病被多数关键试验排除,缺乏随机对照数据
- DOAC药代动力学受肾功能、蛋白尿及P-糖蛋白药物影响
核心结论
- 观察性研究提示DOAC在肾脏病患者中抗栓疗效不劣于传统药物且出血风险更低,但缺乏随机对照试验验证。
研究设计与样本
- 综述总结现有DOAC在肾脏病中应用的文献,非系统检索。
主要发现
- 事后分析、回顾性研究、索赔数据研究和荟萃分析提示DOAC获益可延伸至肾脏病患者。
- 早期数据提示DOAC较维生素K拮抗剂可能减少抗凝相关肾病风险。
- DOAC多经肾清除且显著蛋白结合,药代动力学受肾功能下降和蛋白尿影响。
- DOAC代谢受P-糖蛋白抑制剂和诱导剂影响,包括肾病合并症常用药物。
临床怎么用
- 中重度肾病患者使用DOAC需基于观察性证据权衡疗效与出血风险。
- 关注肾功能和蛋白尿对DOAC药代动力学的影响。
- 注意合并使用P-糖蛋白抑制剂或诱导剂时的药物相互作用。
局限性
- 多数关键DOAC试验排除中重度肾病患者。
- 特定肾病场景缺乏随机对照试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The anticoagulation field is experiencing a renaissance that began with regulatory approval of the direct thrombin inhibitor dabigatran, a direct oral anticoagulant (DOAC), in 2010. The DOAC medication class has rapidly evolved to include the additional approval of 4 direct factor Xa inhibitors. Commensurately, DOAC use has increased and collectively account for the majority of new anticoagulant prescriptions. Despite exclusion of patients with moderate-to-severe kidney disease from most pivotal DOAC trials, DOACs are increasingly used in this setting. An advantage of DOACs is similar or improved antithrombotic efficacy with less bleeding risk when compared with traditional agents. Several post hoc analyses, retrospective studies, claims data studies, and meta-analyses suggest that these benefits extend to patients with kidney disease. However, the lack of randomized controlled trial data in specific kidney disease settings, with their unique pathophysiology, should be a call to action for the kidney community to systematically study these agents, especially because early data suggest that DOACs may pose less risk of anticoagulant-related nephropathy than do vitamin K antagonists. Most DOACs are renally cleared and are significantly protein bound in circulation; thus, the pharmacokinetics of these drugs are influenced by reduced renal function and proteinuria. DOACs are susceptible to altered metabolism by P-glycoprotein inhibitors and inducers, including drugs commonly used for the management of kidney disease comorbidities. We summarize the currently available literature on DOAC use in kidney disease and illustrate knowledge gaps that represent important opportunities for prospective investigation.
引用
- Derebail VK, Rheault MN, Kerlin BA, et al. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019. PMID: 32107019. doi:10.1016/j.kint.2019.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。